Always taking RISK - do your own DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MPXEF MPX Signs a Letter of Intent to Acquire Canadian Licenced Producer Canveda. MPX will acquire the Canveda Shares for a total purchase price of CDN$18 million.
https://www.yahoo.com/amphtml/finance/news/mpx-signs-letter-intent-acquire-110000082.html#click=https://t.co/aoNICB0Yud
I wonder if this turd is ever going to move
Looks interesting bro, going to keep on watch, thanks
Sounds like a Global distribution is starting with int’l distribution first then the US. I expect a similar announcement from AYTU BioScience soon for US market.
$ABCCF $MPXEF on major watch and should continue to make new highs. Keep them on watch. MJ run is beginning once again. Good luck everyone with your trades.
Love this article. German market is going to be great. A sleeper out of this article is ABCann Global IMO. PPS has been crushed but it’s bound for a major move. The Company is well-positioned with over $135 million in cash to accelerate the growth of their business. The Company is expecting to begin exporting cannabis to Australia mid-year, and to Germany close to year-end, and continues to assess opportunities in other international markets.
Canada’s cannabis oil exports rise 300%, boosted by German demand. Canadian medical marijuana is already accessible by most of Germany’s 20,200 pharmacies from suppliers like Aurora, Tilray, Cronos, Maricann, ABcann, CanniMed (now owned by Aurora), Nuuvera (now called Aphria international) and MedReleaf.
https://mjbizdaily.com/canadas-cannabis-oil-exports-rise-300-boosted-by-german-demand/
Canada’s cannabis oil exports rise 300%, boosted by German demand. Canadian medical marijuana is already accessible by most of Germany’s 20,200 pharmacies from suppliers like Aurora, Tilray, Cronos, Maricann, ABcann, CanniMed (now owned by Aurora), Nuuvera (now called Aphria international) and MedReleaf.
https://mjbizdaily.com/canadas-cannabis-oil-exports-rise-300-boosted-by-german-demand/
Canada’s cannabis oil exports rise 300%, boosted by German demand. Canadian medical marijuana is already accessible by most of Germany’s 20,200 pharmacies from suppliers like Aurora, Tilray, Cronos, Maricann, ABcann, CanniMed (now owned by Aurora), Nuuvera (now called Aphria international) and MedReleaf.
https://mjbizdaily.com/canadas-cannabis-oil-exports-rise-300-boosted-by-german-demand/
MPX Bioceutical check out the updated MPX 'mind map' for all things MPX
https://coggle.it/diagram/Wn4H2FnPjgABx4sa/t/screen-shot-2018-02-03-at-1-54-shot-2018-02-16-at-9-11-09-pm/080e4b4694fedcb7f9f528c7ab45e8518453cf29ae7abe05bbbb5310b104e124
Under the terms of the Agreement between AYTU BioScience & Acerus Pharmaceuticals
https://aytubio.com/aytu-bioscience-enters-2-billion-testosterone-replacement-market-acquisition-u-s-commercial-rights-natesto/
Great things happening here, took a position yesterday at .63 and will be looking to add for long term. This is a sleeping giant IMO.
That’s awesome, will definitely check em out, thanks bud. Checkout MPXEF, big things happening there big time.
This is HUGE news for them. I wonder when AUTY Bioscience will PR this news and wonder why they did not. Either way, this is amazing news and just the beginning for major fins for upcoming Q.
Going to have to do some DD here, you got anything? Thanks bud
AYTU- Now That The Stock Dilution Has Passed, It's Time To Pay Attention To One Of The Safest And Most Effective APPROVED Testosterone Drugs On The Market, Natesto.
https://seekingalpha.com/instablog/49116456-tom-cheatham/5143946-aytu-now-stock-dilution-passed-time-pay-attention-one-safest-effective-approved-testosterone
Acerus Announces Licensing of NATESTO® in 19 Central and Latin American Countries
https://www.businesswire.com/news/home/20180413005081/en/Acerus-Announces-Licensing-NATESTO%C2%AE-19-Central-Latin
Not sure, but it was released yesterday April 13, 2018 07:00 AM Eastern Daylight Time
Thanks DBS. We used to be in another ticker while back, can’t remember but it did great, I have a feeling this is going to be much bigger :)
Looks like Natesto is about to go big time.
Acerus Announces Licensing of NATESTO® in 19 Central and Latin American Countries
https://www.businesswire.com/news/home/20180413005081/en/Acerus-Announces-Licensing-NATESTO
AYTU- Now That The Stock Dilution Has Passed, It's Time To Pay Attention To One Of The Safest And Most Effective APPROVED Testosterone Drugs On The Market, Natesto.
Apr. 13, 2018 4:41 PM
https://seekingalpha.com/instablog/49116456-tom-cheatham/5143946-aytu-now-stock-dilution-passed-time-pay-attention-one-safest-effective-approved-testosterone
They have 180 days to meet then requirements and they can also get an extension, I’m not worried about this at all.
Looking good here again. Heading north, buckle up
Awesome day here, got in at .63, will be looking to add next week as well. Huge news today and this is only the beginning, congrats everyone!!!
http://marijuanastocks.com/senate-republican-gardner-agrees-with-trump-on-marijuana-policy/
What happened to your prediction of Near term target .95-1.03
Good to see volume, can’t they give us a damn update though? WOW!
Antibe Therapeutics Engages Blaise Group International for Executive Search
April 11, 2018 08:00 PM Eastern Daylight Time
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) has engaged Blaise Group International (“Blaise Group”), a leading healthcare-focused executive recruitment agency, to augment its global business development expertise. Blaise Group is a leading retained human capital search and strategic services firm exclusively servicing life science organizations on a global basis. In connection with the agreement, Antibe has granted Blaise Group 151,515 options to purchase common shares of the Company that will vest upon the success of Antibe’s recruitment objective. Each option has an exercise price of $0.495, being today’s closing price of the Company’s shares, and will expire April 11, 2021.
https://www.businesswire.com/news/home/20180411006413/en/Antibe-Therapeutics-Engages-Blaise-Group-International-Executive
Antibe Therapeutics Engages Blaise Group International for Executive Search
April 11, 2018 08:00 PM Eastern Daylight Time
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) has engaged Blaise Group International (“Blaise Group”), a leading healthcare-focused executive recruitment agency, to augment its global business development expertise. Blaise Group is a leading retained human capital search and strategic services firm exclusively servicing life science organizations on a global basis. In connection with the agreement, Antibe has granted Blaise Group 151,515 options to purchase common shares of the Company that will vest upon the success of Antibe’s recruitment objective. Each option has an exercise price of $0.495, being today’s closing price of the Company’s shares, and will expire April 11, 2021.
https://www.businesswire.com/news/home/20180411006413/en/Antibe-Therapeutics-Engages-Blaise-Group-International-Executive
$AYTU ENGLEWOOD, Colo., April 3, 2018 /ACCESSWIRE/ – Aytu BioScience, Inc (NASDAQ: AYTU) (the “Company”) will be presenting at this year’s MicroCap Conference on Tuesday, April 10, 2018 at 10:30am.
Conference Overview and Structure
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors. The MicroCap Conference will take place in New York City at the Essex House on April 9th and 10th.
Participating Companies
https://aytubio.com/aytu-bioscience-to-present-at-the-microcap-conference-on-april-10th-in-new-york-city-at-the-essex-house/
$ATE.V $ATBPF April 2018 updated investor presentation!
http://www.antibethera.com/wordpress/pdf/presentations/Antibe%20Investor%20Presentation%20-%20April%202018.pdf
$ATE.V $ATBPF April 2018 updated investor presentation!
http://www.antibethera.com/wordpress/pdf/presentations/Antibe%20Investor%20Presentation%20-%20April%202018.pdf
Nice DD, thanks for sharing, didn’t know of them, maybe I should bump my target a little higher :)
Based on increasing the chance for approval and the price for ATB-346 our new valuation is CAD$1.80.
http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/ATEV-Antibes-Phase-2b-Efficacy-Study-Fully-Funded/default.aspx
$ATBPF Based on increasing the chance for approval and the price for ATB-346 our new valuation is CAD$1.80.
http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/ATEV-Antibes-Phase-2b-Efficacy-Study-Fully-Funded/default.aspx
Has all the making to head to $1+ by next week, holding for a run, good luck all.
Based on increasing the chance for approval and the price for ATB-346 our new valuation is CAD$1.80.
http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/ATEV-Antibes-Phase-2b-Efficacy-Study-Fully-Funded/default.aspx
I decided to move on from Nemus. Been holding this for a very long time and don’t see them doing much for the next few years. This is a long long hold for anyone that wants to see this company turn any profits. OS increasing from mid 20m to 100m is also a concern long term, who knows where SS would be in by the time company is making moves. With that said, company has a great pipeline and a vision, but I’m here to make money also, and i don’t think we will see anything here in a long time.
Good luck to those holding.
GO NEMUS
A detailed summary of the clinical trial results, including secondary endpoints, will be available for release in Q2 2018.
$ATBPF HUGE NEWS.
Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346
https://www.businesswire.com/news/home/20180320005815/en/Antibe-Therapeutics-Announces-Successful-Phase-2B-Gastrointestinal
Clinical trials is what I meant to say.
Looks like continues run is imminent heading into week of March 19. I added more shares today.